Barbara G. McClung, serving as Chief Legal Officer at Caribou Biosciences (NASDAQ: CRBU), executed a sale of 6,938 common shares on February 24, 2026, at a per-share price of $1.96, producing gross proceeds of $13,598. According to a Form 4 filing with the Securities and Exchange Commission, the disposition was made specifically to cover tax obligations arising from the vesting of restricted stock units.
The company's share price has moved higher since the transaction. At the time of reporting, the stock is trading at $2.14 - a rise equivalent to 32% over the last week and a 73% gain compared with its level a year earlier.
Additional insider compensation actions for McClung were disclosed on February 20, 2026. On that date she acquired 45,000 shares of common stock valued at $0, representing restricted stock units that will vest in four equal annual installments beginning February 20, 2027. In the same filing, McClung was also awarded options to purchase 202,500 shares of common stock at an exercise price of $1.80 per share. Those options vest monthly and are scheduled to be fully vested by February 20, 2030.
Market research notes included in filings and related commentary indicate differing perspectives on valuation and prospects. An InvestingPro analysis cited in disclosures states that the stock currently trades below its Fair Value and offers a Pro Research Report for further detail on Caribou Biosciences' outlook.
Separately, Clear Street has initiated coverage of Caribou Biosciences with a Buy rating and set a price target of $13.00. In its initiation note, the firm highlighted optimism about Caribou's work on off-the-shelf allogeneic CAR-T cell therapies and suggested those therapies could be competitive commercially. The initiation represents an analyst view of the companys potential in advancing these therapies.
Contextual summary - The insider sale was identified as a tax-driven transaction tied to RSU vesting. At the same time, McClung's equity compensation package includes RSUs with multi-year vesting and a large option grant that vests through 2030. Market commentary from InvestingPro flags valuation below Fair Value, while Clear Street initiated coverage with a Buy and a $13.00 target, citing optimism for Caribou's allogeneic CAR-T development.